AU2003229548A1 - Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis - Google Patents

Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis

Info

Publication number
AU2003229548A1
AU2003229548A1 AU2003229548A AU2003229548A AU2003229548A1 AU 2003229548 A1 AU2003229548 A1 AU 2003229548A1 AU 2003229548 A AU2003229548 A AU 2003229548A AU 2003229548 A AU2003229548 A AU 2003229548A AU 2003229548 A1 AU2003229548 A1 AU 2003229548A1
Authority
AU
Australia
Prior art keywords
trapidil
pizotifen
cyproheptadine
combination consisting
inhibiting angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003229548A
Inventor
Ines Neubauer
Gotz Nowak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003229548A1 publication Critical patent/AU2003229548A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel medicaments containing a combination consisting of a serotonin antagonist and of trapidil.
AU2003229548A 2002-02-19 2003-02-19 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis Abandoned AU2003229548A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10206941.7 2002-02-19
DE10206941A DE10206941A1 (en) 2002-02-19 2002-02-19 New drugs
PCT/EP2003/001694 WO2003070249A1 (en) 2002-02-19 2003-02-19 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
AU2003229548A1 true AU2003229548A1 (en) 2003-09-09

Family

ID=27740254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003229548A Abandoned AU2003229548A1 (en) 2002-02-19 2003-02-19 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis

Country Status (5)

Country Link
EP (1) EP1478365B1 (en)
AT (1) ATE441416T1 (en)
AU (1) AU2003229548A1 (en)
DE (2) DE10206941A1 (en)
WO (1) WO2003070249A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797427A4 (en) * 2004-09-22 2009-04-08 Odyssey Thera Inc Methods for identifying new drug leads and new therapeutic uses for known drugs
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
NZ608343A (en) * 2007-04-13 2014-09-26 Southern Res Inst Anti-angiogenic agents and methods of use
WO2010006432A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
WO2016179481A1 (en) * 2015-05-07 2016-11-10 Cardelli James Allen Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs
CN111920809B (en) * 2020-09-04 2022-01-07 郑州大学 Application of benzothiidine and salt thereof in preparation of antitumor drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5827773B2 (en) * 1980-02-08 1983-06-11 持田製薬株式会社 Cancer metastasis inhibitor
US4661500A (en) * 1985-08-29 1987-04-28 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US5272159A (en) * 1990-02-26 1993-12-21 Merck & Co., Inc. Adjuncts in cancer chemotherapy

Also Published As

Publication number Publication date
EP1478365A1 (en) 2004-11-24
EP1478365B1 (en) 2009-09-02
ATE441416T1 (en) 2009-09-15
DE10206941A1 (en) 2003-09-25
DE50311867D1 (en) 2009-10-15
WO2003070249A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
MXPA04012691A (en) New compounds.
AU2003259267A1 (en) Substituted aminopyrimidines as neurokinin antagonists
WO2004082623A3 (en) Substituted piperidine compounds
AU2002352633A1 (en) Piperidine compounds for use as orexin receptor antagonist
PL374014A1 (en) Novel phenanthridines having pde 3/4 inhibiting properties
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
UA88163C2 (en) Cgrp antagonists, methods for the production thereof and their use as medicaments
HK1073304A1 (en) Triazole derivatives as tachykinin receptor antagonists
IL150085A0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
AU2002350961A1 (en) Ethylene diamine derivatives and their use as orexin-receptor antagonists
HK1072052A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
EP1675552A4 (en) Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
HK1061563A1 (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv
WO2004074247A3 (en) A1 adenosine receptor antagonists
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
AU2003256922A8 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003229548A1 (en) Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
EP1549655A4 (en) Substituted bicyclic thiophene derivatives, compostions containing such compounds and methods of use
AP2005003196A0 (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
PL371310A1 (en) Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
HUP0202188A2 (en) Tricyclic compounds having spiro piperidine unit, pharmaceutical compositions containing them and intermediates of the compounds
MXPA05006587A (en) Thiazole compounds as integrin receptor antagonists derivatives.
MXPA04001205A (en) Compounds for eliminating and/or relieving anhedonia.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase